ReviewNeurotoxicity research2005
Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases.
Review in Neurotoxicity research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 71 citations in OpenAlex.
- Neuroinflammation and Neurodegenerative Diseases: How Much Do We Still Not Know?Brain sciences · 2023Review
- Trends in perivascular macrophages research from 1997 to 2021: A bibliometric analysis.CNS neuroscience & therapeutics · 2023Article
- Decellularization techniques and their applications for the repair and regeneration of the nervous system.Methods (San Diego, Calif.) · 2020Review
- The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease.Journal of neurovirology · 2019Review
- Adeno-Associated Viral Vector Serotype DJ-Mediated Overexpression of N171-82Q-Mutant Huntingtin in the Striatum of Juvenile Mice Is a New Model for Huntington's Disease.Frontiers in cellular neuroscience · 2018Article
- TREM1: A Potential Therapeutic Target For Alzheimer's Disease.Neurotoxicity research · 2017Article
- Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer's disease.Journal of neuroinflammation · 2016Article
- Microglial pathology.Acta neuropathologica communications · 2014Review
- Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes.Neurochemistry international · 2013Article
- Nanoparticle based galectin-1 gene silencing, implications in methamphetamine regulation of HIV-1 infection in monocyte derived macrophages.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2012Article
- Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease.Journal of neuroinflammation · 2012Article
- Minocycline modulates antigen-specific CTL activity through inactivation of mononuclear phagocytes in patients with HTLV-I associated neurologic disease.Retrovirology · 2012Article
- The role of cell type-specific responses in IFN-β therapy of multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Macrophage bridging conduit trafficking of HIV-1 through the endoplasmic reticulum and Golgi network.Journal of proteome research · 2011Article
- Functional proteomic analysis for regulatory T cell surveillance of the HIV-1-infected macrophage.Journal of proteome research · 2010Article
- Proteomic analyses of monocytes obtained from Hispanic women with HIV-associated dementia show depressed antioxidants.Proteomics. Clinical applications · 2010Article
- The vascular contribution to Alzheimer's disease.Clinical science (London, England : 1979) · 2010Review
- Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders.Journal of neuroimmunology · 2009Article
- NanoART, neuroAIDS and CNS drug delivery.Nanomedicine (London, England) · 2009Review
- Neurodegenerative disorders and nanoformulated drug development.Nanomedicine (London, England) · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Brain mononuclear phagocytes (MP, bone marrow monocyte-derived macrophages, perivascular macrophages, and microglia) function to protect the nervous system by acting as debris scavengers, killers of microbial pathogens, and regulators of immune responses. MP are activated by a variety of environmental cues and such inflammatory responses elicit cell injury and death in the nervous system. MP immunoregulatory responses include secretion of neurotoxic factors, mobilization of adaptive immunity, and cell chemotaxis. This incites tissue remodelling and blood-brain barrier dysfunction. As disease progresses, MP secretions engage neighboring cells in a vicious cycle of autocrine and paracrine amplification of inflammation leading to tissue injury and ultimately destruction. Such pathogenic processes tilt the balance between the relative production of neurotrophic and neurotoxic factors and to disease progression. The ultimate effects that brain MP play in disease revolves "principally" around their roles in neurodegeneration. Importantly, common functions of brain MP in neuroimmunity link highly divergent diseases (for example, human immunodeficiency virus type-one associated dementia, Alzheimer's disease and Parkinson's disease). Research into this process from our own laboratories and those of others seek to harness MP inflammatory processes with the intent of developing therapeutic interventions that block neurodegenerative processes and improve the quality of life in affected people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.